Russia to treat virus cases with anti-malaria drug

Image
AFP Moscow
Last Updated : Apr 17 2020 | 4:52 PM IST

The Russian government has authorised the use of an anti-malarial drug to treat coronavirus patients despite international concerns over its safety and effectiveness.

The government published an order late Thursday allowing the use of hydroxychloroquine on patients after China donated more than 68,000 packs of the tablets to Russia.

The order was published after President Vladimir Putin had a phone conversation with Chinese leader Xi Jinping on Thursday evening.

It said the drug would be distributed to hospitals that are caring for patients who have tested positive for coronavirus or are suspected of having it. It said the drug's safety and effectiveness will be monitored by the state health watchdog.

Hydroxychloroquine has been used for decades against malaria and is being tested worldwide against the virus along with another anti-malarial drug, chloroquine.

Both have potentially serious side effects, especially in high doses or when administered with other medications, and their use to treat the virus is still experimental, without having gone through exhaustive clinical testing.

Some see them as a potential weapon in the fight against the virus while there is still no proven cure or vaccine. Hydroxychloroquine has shown early promise against COVID-19 in small-scale studies in France and China to reduce virus levels among people badly infected.

US President Donald Trump has touted it as a coronavirus treatment and in the US a limited emergency-use authorisation has been granted to the drug.

But many scientists are urging caution until larger trials show whether it is safe and effective.

The European Medicines Agency has said that both chloroquine and hydroxychloroquine need to go through clinical trials and should not be used to treat virus cases unless there is a "national emergency.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 17 2020 | 4:52 PM IST

Next Story